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Abstract
Background: Current diagnostic tests for hereditary spherocytosis (HS) focus on the detection of hemolysis or indirectly
assessing defects of membrane protein, whereas direct methods to detect protein defects are complicated and difficult
to implement. In the present study, we investigated the patterns of genetic variation associated with HS among patients
clinically diagnosed with HS.
Methods: Multi-gene targeted sequencing of 43 genes (17 RBC membrane protein-encoding genes, 20 RBC enzyme-
encoding genes, and six additional genes for the differential diagnosis) was performed using the Illumina HiSeq platform.
Results: Among 59 patients with HS, 50 (84.7%) had one or more significant variants in a RBC membrane protein-
encoding genes. A total of 54 significant variants including 46 novel mutations were detected in six RBC membrane
protein-encoding genes, with the highest number of variants found in SPTB (n = 28), and followed by ANK1 (n = 19),
SLC4A1 (n = 3), SPTA1 (n = 2), EPB41 (n= 1), and EPB42 (n = 1). Concurrent mutations of genes encoding RBC enzymes
(ALDOB, GAPDH, and GSR) were detected in three patients. UGT1A1 mutations were present in 24 patients (40.7%). Positive
rate of osmotic fragility test was 86.8% among patients harboring HS-related gene mutations.
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Conclusions: This constitutes the first large-scaled genetic study of Korean patients with HS. We demonstrated that
multi-gene target sequencing is sensitive and feasible that can be used as a powerful tool for diagnosing HS. Considering
the discrepancies of clinical and molecular diagnoses of HS, our findings suggest that molecular genetic analysis is
required for accurate diagnosis of HS.
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Background
Hereditary spherocytosis (HS) is the most common
cause of hereditary hemolytic anemia (HHA) character-
ized by the presence of spherocytes in peripheral blood
smear (PBS) [1, 2]. HS occurs in 1 in 2000 Caucasians,
with less common frequency in Asians [1, 3, 4]. The
crude incidence of HS in Korea was reported as 1 in
every 5000 births [5]. Approximately 75% cases of HS
are inherited as autosomal dominant (AD) mutations,
whereas the remaining cases involve autosomal recessive
(AR) or de-novo mutations [1].
HS is caused by a deficiency in or dysfunction of mem-
brane proteins, including spectrin, ankyrin 1, band 3, and
protein 4.2, associated with the RBC cytoskeleton [3, 4, 6].
Defective membrane proteins disrupt the vertical linkage
between the RBC membrane cytoskeleton and the
phospholipid bilayer, causing RBCs to lose its biconcave
characteristics and become spherical in shape [3, 4, 6].
This abnormal RBC morphology leads to osmotically fra-
gile cells that are selectively trapped and destroyed in the
spleen [3, 4, 6]. A major clinical manifestation of HS is
hemolytic anemia, which exhibits a wide range of clinical
manifestations from asymptomatic to life-threatening
anemia requiring regular RBC transfusions [1, 2]. Other
clinical symptoms include splenomegaly, jaundice, and
gallstones, depending on disease severity [1, 2].
We have been operating the Korean Hereditary
Hemolytic Anemia Working Party (KHHAWP) of the Ko-
rean Society of Hematology for 7 years since 2010, which
name has been changed to RBC Disorder Working Party
since November 2016. From 2007 to 2011, 195 patients
(121 males and 74 females) diagnosed with HHA from 25
institutions were registered [7]. The KHHAWP presented
standard operating procedure (SOP) for the diagnosis of
HHA (Fig. 1) [5], which is similar to ICSH (International
Council for Standardization in Haematology) guideline [8]
except for excluding acid glycerol lysis time test as a
screening test. Instead of gel electrophoresis analysis of
erythrocyte membranes, the KHHAWP adopted mass
spectrometry method as a confirmatory test, which is per-
formed in one central laboratory in Korea.
The diagnosis of HS is based upon a combination of
positive family history, clinical features and presence of
spherocytes in PBS, which are detectable in 97% of
patients [9]. When the diagnosis of HS is equivocal,
additional laboratory tests are recommended such as os-
motic fragility test (OFT), autohemolysis test, flow cy-
tometry [OFT and eosin-5-maleimide (EMA) binding
test] for screening test, and protein analysis using gel
electrophoresis or mass spectrometry can be additionally
tested [10–16]. However, none of the current diagnostic
test can detect all patients with HS.
Considering the limitations of existing diagnostic tests,
development of a simple and direct method to measure
RBC membrane protein abnormalities to confirm HS is re-
quired. Analysis of RBC membrane protein-encoding genes
is expected that it can be used complementarily with the
conventional confirmatory tests [1, 11]. Multi-gene target
sequencing for RBC membrane protein-encoding genes is
feasible and reliable diagnostic method to detect mutations
in patients affected by various disorders of the RBC mem-
brane. Particularly, gene testing is important in young chil-
dren with congenital anemia, transfusion-dependent
patients, and in families with variable clinical expression or
complex inheritance patterns [17–19].
In the present study, we investigated the genetic vari-
ation of RBC membrane protein-encoding genes using
multi-gene target sequencing, comparing with clinical
features. A total of 43 genes was included; 17 RBC mem-
brane protein-encoding genes and 20 RBC enzyme-
encoding genes, in context with six additional candidate
genes for the purpose of differential diagnoses [thalas-
semia, congenital dyserythropoietic anemia (CDA),




A total of 59 patients with HS including 31 males and
28 females with a median age of 7 years (range: 1–81
years), were registered between July 2013 and July 2014
from the pediatrics and internal medicine departments
of 25 institutions in Korea. HS was diagnosed according
to the SOP recommended by the KHHAWP of the Ko-
rean Society of Hematology (Fig. 1) [5].
Along with clinical data including age, sex, symptoms
and family history, we collected the results of laboratory
tests including CBC with RBC index, reticulocyte count,
total and direct bilirubin concentration, lactate dehydro-
genase (LDH), iron, total iron-binding capacity (TIBC),
Choi et al. Orphanet Journal of Rare Diseases          (2019) 14:114 Page 2 of 13
ferritin, PBS, and OFT by reviewing medical records
(Table 1). Blood samples were collected from each
patient after obtaining their written consent.
Targeted sequencing
To gain insight into the genetic variations, we per-
formed targeted sequencing for 43 gene panel (Add-
itional file 1: Table S1). gDNA shearing to generate the
standard library and the hybridization step targeting
only exonic regions were performed by Celemics Inc.
(Seoul, Korea). The final quality was assessed using
the Agilent 2200 TapeStation System (Santa Clara,
CA, USA). We sequenced a total target length of
259-kb regions using the paired-end 150-bp rapid-run
sequencing mode on an Illumina HiSeq 2500 platform.
The mean sequencing depth for the targeted regions
(259-kb) was 231-fold (n = 59). Because a matched
control sample was not included in this study, we ap-
plied a stringent variant selection pipeline to prioritize
the high-confidence set of somatic mutations.
Variant calling
The filtration process was performed as follows. Variants
within non-exonic regions were removed. Variants that
do not have enough depth were also filtered out to re-
move false positives. Common variants on 1000 genome
projects with more than 5% of allele frequency were fil-
tered out. CADD score shows predictive pathogenicity
of variants. It considers diverse annotations from allelic
diversity to functionality, in order to estimate pathogenic
variants. In this study, CADD scores below 10 were
cut-off for filtration. After these filters, in-house variants
were also removed to make filtered variant lists. Valid-
ation of variant call was performed by target gene
sequencing of involved genes.
Simulation of the effect of mutated genes on protein
structure
To predict how gene mutation affect protein structure, we
visualized three-dimensional (3-D) spatial protein struc-
ture following acquisition of their structural information
(http://www.proteinmodelportal.org) (Additional file 1:
Fig. 1 Standard operating procedure for the diagnosis of hereditary hemolytic anemia (HHA) by HHA Working Party of Korean Society of
Hematology [5]
Choi et al. Orphanet Journal of Rare Diseases          (2019) 14:114 Page 3 of 13









P value between group
with mutation vs.
without mutation
Sex, n (%) 0.597
Male 31 (52.0) 27 (54.0) 4 (44.4)
Female 28 (48.0) 23 (46.0) 5 (55.6)
Age (years) 0.566
Median 7 7 8
Range 1–81 1–81 2–17
Family history of HS, n (%) 0.139
Positive 20 (33.9) 16 (32.0) 4 (44.4)
Negative 39 (66.1) 34 (68.0) 5 (55.6)
Clinical symptoms, n (%)
Splenomegaly 38/59 (64.4) 31/50 (62.0) 7/9 (77.8) 0.363
Neontal jaundice 28/54 (51.9) 24/45 (53.3) 4/9 (44.4) 0.724
Hepatomegaly 9/53 (17.0) 9/44 (20.5) 1/9 (11.1) 1.000
Splenectomy 13/58 (22.4) 10/49 (20.4) 3/9 (40.0) 0.398
Aplastic crisis 14/56 (25.0) 11/47 (23.4) 3/9 (30.0) 0.676
Gallstones 10/57 (17.5) 9/48 (18.8) 1/9 (33.3) 1.000
Hematologic parameters, mean
Hemoglobin (g/dL) (range) 8.4 (3.6–13.6) 8.4 (3.6–13.6) 8.3 (5.8–12.1) 0.476
MCV (fL) (range) 80.9 (62.3–107.0) 80.6 (62.3–107.0) 85.3 (70.4–107.0) 0.209
MCHC (g/dL) (range) 35.3 (30.8–38.2) 35.2 (30.8–38.2) 35.2 (31.5–37.9) 0.279
Markers of hemolysis, mean
Reticulocyte count (%) (range) 7.5 (0.5–24.8) 7.4 (0.5–24.8) 7.2 (3.4–13.3) 0.461
Total bilirubin (mg/dL) (range) 4.1 (0.8–19.1) 4.0 (0.8–19.1) 4.3 (1.1–6.4) 0.320
Direct bilirubin (mg/dL) (range) 0.7 (0.2–1.3) 0.7 (0.3–1.3) 0.6 (0.4–0.8) 0.640
LDH (IU/L) (range) 508 (187–1557) 522 (187–1557) 448 (198–737) 0.843
Iron status parameters, mean
Iron (μr/dL) (range) 101 (26–245) 98 (26–159) 111 (51–245) 0.198
TIBC (μT/dL) (range) 266 (108–486) 269 (108–486) 241 (195–274) 0.769
Ferritin (ng/mL) (range) 342 (32–4671) 360 (32–4671) 339 (74–278) 0.657
Grading of peripheral spherocytes, n (%) 0.622
0 5 (8.5) 4 (8.0) 1 (11.1)
1+ or slight (2–5%), 18 (30.5) 15 (30.0) 3 (33.3)
2+ or moderate (6–15%), 20 (33.9) 16 (32.0) 4 (44.4)
3+ or marked (> 16%) 16 (27.1) 15 (30.0) 1 (11.1)
Sex, n (%) 0.597
Male 31 (52.0) 27 (54.0) 4 (44.4)
Female 28 (48.0) 23 (46.0) 5 (55.6)
Severity, n (%) 0.678
Mild 6 (10.2) 5 (10.0) 1 (11.1)
Moderate 27 (45.8) 24 (48.0) 3 (33.3)
Severe 26 (44.1) 21 (42.0) 5 (55.6)
Osmotic fragility tests, n (%) 0.614
Positive 41 (69.5) 33 (66.0) 8 (88.9)
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Table S2). We used PyMOL (http://www.pymol.org) to
visualize 3-D representations of the protein, modified pro-
tein structures based on genetic mutation profiles from
next-generation sequencing (NGS) results.
Statistical analyses
Stata/SE (v.14; StataCorp, College Station, TX, USA) was
used for data analyses. Statistical differences in terms of
continuous clinical characteristic variables were esti-
mated by two sample t test. The significance of differ-
ences in categorical variables between groups was
determined by the Pearson χ2 test or Fisher’s exact test.
The level of significance was set at P < 0.05.
Results
Clinical characteristics
Among 59 patients with HS, 20 (33.9%) had a family his-
tory of HS, whereas symptoms of splenomegaly, neo-
natal jaundice, and hepatomegaly were exhibited in 38 of
59 (64.4%), 28 of 54 (51.9%), and 10 of 59 (16.7%) pa-
tients, respectively. Mean values for laboratory tests were
as follows: hemoglobin concentration 8.4 g/dL (3.6–13.6
g/dL); corpuscular volume 80.9 fL (62.3–107.0 fL); cor-
puscular hemoglobin concentration 35.3 g/dL (30.8–
38.2 g/dL); reticulocyte count indicating hemolysis 7.5%
(0.5–24.8%); total bilirubin/direct bilirubin 4.1/0.7 mg/dL
(0.8–19.1/0.2–1.3 mg/dL); LDH 508 IU/L (187–1557 IU/
L); parameters representing iron profile, including iron
101 μg/dL (26–245 μg/dL), TIBC 266 μg/dL (108–
486 μg/dL); and ferritin concentration, 342 ng/mL (32–
4671 ng/mL). PBS was rated for spherocytes on a
four-point scale [20] from 0, 1+ or slight (2–5%), 2+ or
moderate (6–15%), and 3+ or marked (> 16%) and the
number of smears returning 0, 1+ or slight, 2+ or mod-
erate and 3+ or marked were 5 (8.5%), 18 (30.5%), 20
(33.9%), and 16 (27.1%) patients, respectively. According
to HS-severity criteria [11], severe, moderate, and mild
cases were 26 (44.1%), 27 (45.8%), and 6 (10.2%) pa-
tients, respectively (Table 1).
Variants profile of RBC membrane protein-encoding
genes
Among 17 RBC membrane protein-encoding genes
examined, significant disease-related mutations were ob-
served in six: SPTB (spectrin, beta), ANK1 (ankyrin 1),
SLC4A1 (solute carrier family 4, member 1), SPTA1
(spectrin, alpha 1), EPB41 (erythrocyte membrane pro-
tein band 4.1), and EPB42 (erythrocyte membrane pro-
tein band 4.2) (Fig. 2). A total of 54 significant
mutations were observed, of which eight were previously
reported as pathogenic in patients with HS and 46 vari-
ants were novel mutations (Additional file 1: Table S3).
The highest number of mutations were found in SPTB
(n = 28), and followed by ANK1 (n = 19), SLC4A1 (n = 3),
SPTA1 (n = 2), EPB41 (n = 1), and EPB42 (n = 1). Ac-
cording to the American College of Medical Genetics
and Genomics guidelines [21], 12 were pathogenic muta-
tions (including eight previously reported variants), 29
were likely pathogenic mutations, and 13 were classified
as having uncertain significance. All the variants have
been confirmed by Sanger sequencing using 35 primer
sets (Additional file 1: Table S4).
Variant characteristics in patients with HS
Among 59 patients with HS, 50 (84.7%) had at least one
mutation in a RBC membrane protein-encoding gene
(Fig. 3). Twenty eight patients carried mutations in the
SPTB gene, and 20 patients had mutations in the ANK1
gene. Forty patients (67.8%) carried a single mutation,
and 10 patients (16.9%) carried two mutations. Among
40 patients with a single mutation, the most frequently
mutated genes were SPTB and ANK1, which were mu-
tated in 21 and 17 patients, respectively. The SCL4A1
mutation was found in two patients. Among the 10 pa-
tients harboring two mutations, one carried two muta-
tions in a single gene (ANK1), and three patients carried
mutations in both SPTB and SPTA1. Combinations of
mutations in SPTB and ANK1, SPTB and EPB41, and
SPTB and EPB42 were detected in one patient each. In
addition, combination with RBC enzyme-encoding gene
mutations were found in three patients [SLC4A1 and
GAPDH (glyceraldehyde-3-phosphate dehydrogenase),
ANK1 and GSR (glutathione reductase), SPTB and
ALDOB (aldolase B)] (Additional file 1: Table S5).
Nine patients carried no mutation on the RBC mem-
brane protein- or enzyme-encoding genes. Coexisting mu-
tations of UGT1A1 (UDP glycosyltransferase 1 family,
polypeptide A1) gene were detected in 24 of 59 HS pa-
tients (40.7%), with UGT1A1 mutations combined with
other gene mutations in 20 patients and without other
gene mutation in four patients (Table 2, Additional file 1:
Table S6). Total bilirubin level or presence of neonatal









P value between group
with mutation vs.
without mutation
Negative 6 (10.2) 5 (10.0) 1 (11.1)
NA 12 (20.3) 12 (24.0) 0
Abbreviation: HS hereditary spherocytosis, NA not assessable
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Fig. 2 Characteristics of significant variants for RBC membrane protein-encoding genes; SPTB, ANK1, SLC4A1, SPTA1, EPB41, EPB42. Abbreviations: SPTB,
spectrin, beta; ANK1, ankyrin 1; SLC4A1, solute carrier family 4, member 1; SPTA1, spectrin, alpha 1; EPB41, erythrocyte membrane protein band 4.1; EPB42,
erythrocyte membrane protein band 4.2
Fig. 3 Number of patients with RBC membrane protein-encoding gene mutations. Abbreviations: SPTB, spectrin, beta; SPTA1, spectrin, alpha 1; EPB41,
erythrocyte membrane protein band 4.1; EPB42, erythrocyte membrane protein band 4.2; ALDOB, aldolase B; ANK1, ankyrin 1; GSR, glutathione reductase;
SLC4A1, solute carrier family 4, member 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase
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Table 2 Gene mutations, laboratory tests and clinical characteristics
Patient ID Membrane
gene mutation






1 SPTB, EPB41 UGT1A1 NA ♦ ▲▲▲ SDS-PAGE (Spectrin)
2 ANK1 + ♦♦♦ (HA, father) ▲▲
3 SPTB NA ♦♦ AD ▲▲▲ Flow cytometrya
4 SPTB UGT1A1 + ♦♦ ▲▲
5 + ♦♦ ● AD ▲▲▲ SDS-PAGE (Spectrin)
6 ANK1 – ♦♦ ● ▲▲▲ SDS-PAGE (Spectrin)
7 SPTB + ♦ ▲▲▲
8 SPTB, SPTA1 + ♦ AD ▲▲▲
9 SPTB, SPTA1 NA ♦ AD ▲▲▲ Flow cytometrya
10 + ♦♦ ● (HA, mother) ▲▲▲
11c SPTB UGT1A1 NA ♦♦♦ ▲▲▲
12 ANK1 + ♦♦ ● ▲▲▲
13 SPTB UGT1A1 + ♦ ▲▲
14 + ♦ ● AD ▲▲▲
15 ANK1b NA ♦♦ AD ▲▲ SDS-PAGE (Spectrin)
16 ANK1b UGT1A1 NA ♦♦♦ AD ▲▲▲
17 UGT1A1 + ♦♦♦ ▲▲
18 ANK1 NA ♦♦♦ AD ▲▲▲
19 ANK1 UGT1A1, UGT1A1 + ♦♦ ▲▲
20 SPTB, SPTA1 UGT1A1 – ♦♦ AD ▲▲▲
21c SLC4A1b UGT1A1 NA – (HA, sibling) ▲▲
22 UGT1A1 + ♦ AD ▲▲▲
23 SPTB + ♦♦♦ AD ▲▲▲
24 UGT1A1 + ♦♦ (HA, mother) ▲▲▲
25c ANK1b NA ♦♦♦ ▲▲
26 ANK1 + ♦♦♦ ● AD ▲▲
27 ANK1 + ♦ ▲▲▲
28 SPTB + ♦♦ ● AD ▲▲
29 ANK1b GSR + ♦♦ ▲▲
30 SPTB ALDOB + ♦♦♦ ▲▲
31c SPTB – NA ♦♦♦ ▲▲▲
32 SLC4A1b UGT1A1, UGT1A1 + ♦♦♦ ▲▲
33 SPTB UGT1A1 + ♦♦ ● ▲▲▲
34 SPTB – – ♦ AD ▲▲
35 SPTBb, EPB42 UGT1A1 + – ▲▲ Autohemolysis
36 SPTB + ♦♦ ● ▲▲
37 ANK1 + ♦♦ ● ▲▲
38 UGT1A1 + ♦ ▲ SDS-PAGE (Spectrin)
39c ANK1 UGT1A1 – ♦ ▲
40 SPTB + ♦♦ ● ▲▲▲
41 ANK1 + ♦♦♦ ▲
42 ANK1 + ♦♦ ▲▲▲
43c ANK1, ANK1 UGT1A1 NA ♦ ▲▲
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jaundice did not differ significantly from those without
UGT1A1 mutations.
Genotype and phenotype correlations in patients with HS
Comparisons of laboratory findings and clinical charac-
teristics showed no significant differences in hematologic
parameters, hemolysis markers, iron status parameters,
sex, family history of HS, number of splenectomized pa-
tients, and disease severity according to the gene muta-
tion type and number of mutation or presence of
UGT1A1 mutation (Table 1, Additional file 1: Table S6).
Among 59 patients with HS, nine patients (15.3%)
without mutation associated with RBC membrane pro-
tein-encoding genes showed similar baseline character-
istics in most aspects as compared with those with
mutations (Table 1). Median age of patients without
mutation was 8 years, and the proportion of family his-
tory, clinical symptoms, grading of peripheral sphero-
cytes, and OFT results did not differ significantly from
those with mutation.
Intercorrelations between gene mutations and laboratory
findings: OFT, the presence of spherocytes in PBS, and
gene mutations
The results of genetic test were matched with routine
diagnostic tests for HS including OFT and the presence
of spherocytes in PBS (Table 3, Fig. 4). Among 59 pa-
tients with clinical HS, results of NaCl induced OFT
(room temperature and/or 24 h incubated) was avail-
able in 47 patients and 41 of them (87.2%) showed posi-
tive results (Additional file 1: Figure S2). Thirty three of
47 patients (70.2%) showed positivity in both OFT and
gene test, while one patients (2.1%) showed negative re-
sults in both OFT and gene test. In six out of 47 pa-
tients (12.7%) with negative OFT, five carried mutations
in RBC membrane protein-encoding genes. Among 38
patients harboring HS-related gene mutations, 33
showed positive OFT (86.8%).
Spherocytes in PBS were present in 54 of 59 patients
(91.5%). Among five patients without spherocytes in
PBS, four carried mutations in RBC membrane protein-
encoding genes (Additional file 1: Table S7). One of 59
patients who had anemia and family history of HS
showed negative results on all three tests.
Discussion
Using multi-gene target sequencing, 50 of 59 patients
(84.7%) of clinically diagnosed HS proved to be molecu-
lar HS and three patients harbored coexisting gene mu-
tations of RBC enzymes (ALDOB, GAPDH, and GSR) in
this study. Mutations of six kinds of RBC membrane
Table 2 Gene mutations, laboratory tests and clinical characteristics (Continued)
Patient ID Membrane
gene mutation






44 SPTB,ANK1 UGT1A1 + ♦ ▲▲
45 ANK1 UGT1A1 + ♦♦♦ ▲▲
46 SPTB UGT1A1 + ♦♦♦ ▲▲
47 SPTB + ♦ (HA, sibling) ▲▲▲
48c SPTBb NA ♦ ▲▲▲
49c SPTB UGT1A1 + – ▲▲
50 ANK1 + – AD ▲▲
51 SPTB UGT1A1 + ♦ AD ▲▲
52 + ♦♦ ▲▲
53 ANK1 + ♦ ▲
54 – – ● AD ▲▲▲
55 SPTB – ♦♦♦ AD ▲
56 SLC4A1 UGT1A1, GAPDH + ♦ ▲
57 SPTB + ♦♦♦ AD ▲▲▲
58 SPTB UGT1A1 + ♦♦ AD ▲▲
59 SPTB + ♦ ▲▲▲
aFlow cytometry (OFT and EMA binding test), bPreviously reported variants (see Additional file 1: Table S3), cEight patients who did not meet the diagnostic
criteria of HS without genetic testing
PB spherocytes [20] ♦, 1+; ♦♦, 2+; ♦♦♦, 3+, Severity of HS [8] ▲, mild; ▲▲, moderate; ▲▲▲, severe
Abbreviations: AD autosomal dominant, ALDOB aldolase B, ANK1 ankyrin 1, EPB41 erythrocyte membrane protein band 4.1, EPB42 erythrocyte membrane protein
band 4.2, GAPDH glyceraldehyde-3-phosphate dehydrogenase, GSR glutathione reductase, HA hemolytic anemia, SLC4A1 solute carrier family 4, member 1, SPTA1
spectrin, alpha 1, SPTB spectrin, beta, UGT1A1, UDP glycosyltransferase 1 family, polypeptide A1, OFT osmotic fragility test, NA not assessable
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protein-encoding genes (total 54 variants) were de-
tected in order of SPTB, ANK1, SLC4A1, SPTA1,
EPB41, and EPB42.
To find whether there is an ethnic difference in HS
related variants, we reviewed the literatures on the re-
ports of HS related mutations in comparison with the
results of the present study, although the methods are
different among reported mutations of HS. Table 4
shows summary of comparison among previous reports
by NGS [22–24]. With regards to the frequency of mu-
tated gene, the SPTA1 mutation was the most common
followed by the SPTB mutation in the reports from the
United States [22, 23]. Meanwhile, a study in Netherland
revealed that the ANK1 mutation was the most common
mutation followed by the SPTA1 mutation [24]. In the
present study, SPTB mutations was the most common
mutation, followed by ANK1 mutations. Particularly note-
worthy, SPTA1 mutations was rarely detected, compared
to that of the United States. Briefly, mutation frequency by
NGS study in Korean was different from those of Cauca-
sian. Korean patients with HS showed higher frequency of
ANK1 mutation. Consistent with our study, another study
in Korea reported that 25 patients with HS carried one
heterozygous mutation of ANK1 (n = 13) or SPTB (n = 12)
but none carried mutations in SPTA1, SLC4A1, or EPB42
by Sanger sequencing [25]. Previous molecular testing
demonstrated that mutations in the ANK1, SPTB,
SLC4A1, SPTA1, and EPB42 genes account for 60, 10, 15,
Table 3 Comparison of OFT, PBS and gene test results in patients with HS
RBC membrane protein-encoding genes
No. of patients with mutation (%) No. of patients without mutation (%)
OFT
(n = 47)
Positive 33 (70.2) 8 (17.0)
Negative 5 (10.6) 1 (2.1)
PBS
(n = 59)
Positive 46 (78.0) 8 (13.6)
Negative 4 (6.8) 1 (1.7)
Abbreviation: OFT osmotic fragility test, PBS peripheral blood cell smear
Fig. 4 A diagram showing the number of patients with positive results of gene mutation, osmotic fragility test, and peripheral blood (PB)
spherocytes in 58 of 59 patients with HS. One of 59 patients who had anemia and family history of HS showed negative result on all three tests
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10, and 5% cases of HS, respectively, in the United States
and Europe [26, 27].
Ethnic differences in RBC membrane protein defects
were also reported in previous studies according to sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) analyses (Table 5) [9, 16, 28–32]. A Korean study in
2000 [28] reported that protein 4.2 defects were detected at
a higher frequency than those of band 3 in the United
States and Europe. That study also reported that most de-
fects were found in ankyrin 1 according to SDS-PAGE ana-
lysis, whereas most mutations were detected in the SPTB
followed by ANK1, according to our NGS results. Addition-
ally, protein defects were not observed was nine out of 27
patients (33.3%) [28]. Meanwhile, single defects in band 3
and spectrin constitute the primary variants reported in
Italy [9, 16], and a combined defect in spectrin/ankyrin is
frequently detected in patients in the United States and
Spain [6, 29, 30]. Regarding to the incidence of HS, an inci-
dence of Japan is highest among Asian countries, and the
defect in the 4.2 protein in Japan is more frequent as com-
pared to the United States and Europe [31, 32]. Those dif-
ferent profiles of HS among countries might be due to
complexity associated with SDS-PAGE methods and lack of
objectiveness in the interpretation of the results. The
interpretation of SDS-PAGE is based on the comparison
with normal healthy control. For that reason, the
standardization is not possible and the comparison of
SDS-PAGE results cannot give a meaningful conclusion. By
contrast, nucleotide sequence analysis gives us straightfor-
ward results, and the interpretation of results is objective.
Inherited pattern of HS differs depending on the gene.
In most HS patients, inheritance is AD and each of HS
patients has a unique mutation [11]. However, SPTA1 or
EPB42 mutation is inherited with AR pattern. Rarely,
double dominant HS due to defects in SLC4A1 or SPTB
are reported [33], which results in fetal death or severe
transfusion-dependent hemolytic anemia presenting in
the neonatal period. SPTB and SPTA1 mutations can be
AD or de novo, whereas ANK1mutation can be AD, AR,
or de novo. SLC4A1 mutation is AD and EPB42 is AR.
Inherited pattern is not clearly revealed in EPB41. Of
note, all the significant variants in RBC membrane
protein-encoding genes are heterozygous. Hence, muta-
tions of genes inherited in AR pattern such as EPB41
and EPB42 gene possibly cannot be a direct cause of HS,
requiring additional mutation to cause hemolytic pheno-
type. In the present study, two patients harboring EPB41
and EPB42 mutations also carried another mutation in
Table 4 NGS results of RBC membrane protein-encoding genes in patients with HS
RBC membrane-encoding gene USA 1 [22] USA 2 [23] Netherlands [24] Korea (this study)
No. of patients with mutation (%) 10/20a (50.0) 16 /19b (84.2) 52 /66 (78.9) 50/59 (84.7)
No. of total mutations 13 21 73 57
No. of different variants 11 15 53 54
ANK1 1 3 14 19
SPTA 6 5 25 2
SPTB 4 4 8 28
SCL4A1 0 3 4 3
EBP41 NA 0 1 1
EBP42 NA 0 1 1
aincluding 2 patients suspected having hereditary elliptocytosis
bincluding patients with diagnosed as HHA
Abbreviation; NA not assessable
Table 5 Literature review on SDS-PAGE results of RBC membrane protein abnormalities in patients with HS (%)
















Band 3 23 (26) 158 (53) 10 (18) 38 (23) 0 (20) 15 (32) 3 (11)
Spectrin only 36 (41) 98 (33) 7 (13) 0 19 (31) 0 8 (15) 2 (7)
Ankyrin only 0 13 (4)† 0 0 4(6) (7) 1 (2) 8 (30)
Spectrin/ankyrin 16 (18) 6 (11) 100 (60) 34 (55) 0 1 (2) 1 (4)
Other combination – – – – – – 15 (34) –
4.2 protein 6 (7) 2 (1) 0 3 (2) 0 (45) 3 (6) 4 (15)
Undetected 6 (7) 29 (10) 32 (58) 25 (15) 5 (8) (28) 4 (9) 9 (33)
*Only % without the number of the patients was presented in this study
†Including both Ankyrin only and Spectrin/ankyrin
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the SPTB gene (EPB41 and SPTB, EPB42 and SPTB in
each patient).
Interestingly, concurrent mutations of genes encod-
ing RBC enzymes (ALDOB, GAPDH, and GSR) were
detected along with heterozygous mutations of RBC
membrane protein-encoding genes in three patients.
Further analysis of enzyme activities in these patients is
necessary for validation. Of the 59 patients with HS ex-
amined in this study, 24 (40.7%) had significant
UGT1A1 variants. It was reported that a polymorphism
of UGT1A1 gene promoter homozygous insertion of
TA pairs (genotype UGT1A1*28/*28) might results in a
decrease in bilirubin glucuronidation activity, leading
to hyperbilirubinemia and late complication of patients
with HS, such as development gallstones [34, 35]. In
contrast, there are debates on the late impact of geno-
type of UGT1A1 [36]. However, a polymorphism of
UGT1A1 gene promoter was not included in this study.
Based on the results of the present study showing high
frequency of UGT1A1 variant with low enzymatic
activity, we infer that genotyping of UGT1A1 poly-
morphism might help to predict the development of
gallstones in HS.
The laboratory diagnosis of HS routinely relies on the
presence of spherocytes in PBS, OFT, and more
recently EMA binding test [10, 11, 37, 38]. Yet, there is
no single test that can confirm HS. We have matched
the results of genetic test with those of routine diagnos-
tic tests (Table 3). Among 50 patients harboring muta-
tions of encoding RBC membrane protein, 86.8%
showed positive OFT, while 70.2% of clinical HS
showed positive OFT. On the contrary, eight patients
(17.0%) with positive OFT result revealed no mutation
of membrane genes, and five (10.6%) with negative
OFT proved to harbor membrane gene mutation. Re-
garding to spherocytes, four of 50 patients (8%) harbor-
ing membrane gene mutation did not show spherocytes
in PBS. We retrospectively reviewed PBS to determine
the presence of spherocytes in those four patients who
did not show spherocytes in PBS but with RBC mem-
brane protein-encoding gene mutations. However, we
could not detect additional spherocytes. Conclusively,
OFT and spherocytes in PBS can be used in conjunc-
tion with genetic test for the -diagnosis of HS, giving
higher sensitivity and specificity.
With regards to the genotype-phenotype relationship,
we could not find any correlation between the genetic
test results and clinical characteristics including disease
severity, mean hemoglobin concentrations, splenomeg-
aly, gallstones, aplastic crisis and bilirubin levels ac-
cording to mutations of four genes (SPTB, ANK1,
SPTA1, and SLC4A1), except EPB41 and EPB42, which
were found in only one patient each, However, one
study reported that anemia was most severe in HS
patients with mutations on the ANK1 spectrin-binding
domain and splenectomy was more frequently per-
formed in patients with ANK1 mutations than in those
with SPTB mutations [25]. In addition, the other re-
ported that hemoglobin concentration was slightly
lower in patients with spectrin deficiency than with
band 3 deficiency [39].
Other NGS study on RBC membrane diseases re-
ported similar results (86.3%, 44 of 51 patients) [24].
This finding suggested a close correlation between clin-
ical diagnosis and gene mutations. In the present study,
molecular test could detect additional HS which could
be missed without molecular test (Fig. 4). Furthermore,
molecular test would be an effective method for neo-
nates or transfused individuals, since the result of OFT
and spherocytes in PBS can be unreliable, especially
when the patients are transfused [11]. Collectively, our
results suggest that mutation analyses will complement
with other conventional tests for accurate diagnosis of
HS. We consider the molecular test needs to be inte-
grated to the diagnostic criteria of HS.
The limitation of this study is that we did not per-
form the analysis on RBC membrane protein as a valid-
ation. Instead, we simulated 3-D spatial structure of
protein encoding mutated genes, predicting the effects
of gene mutations in silico. Although exact changes in
protein structure cannot be predicted based on 3-D
spatial structure, large-scale modification of the protein
due to frame shift or nonsense mutations can be visual-
ized and subsequent functional changes can be ex-
pected from structure analysis. Further family study or
functional studies using knockout mice needs to be
conducted to validate the significance of variants. An-
other limitation is that we could not match the results
of EMA binding test with genetic results, since our
study was done retrospectively. Nine patients who did
not harbor gene mutation of RBC membrane protein
(Additional file 1: Table S8), satisfied the diagnostic cri-
teria of HS suggested in the guideline [11]. Though they
satisfied those criteria, there are two possibilities that
they have other forms of hemolytic anemia or other
membrane gene mutations that is not included in our
multi-gene panel (e.g. channel defects such as KCNN4
as found in hereditary stomatocytosis) [40].
When we target the most frequent mutations only,
composition of gene panel with genes over 10% fre-
quency (SPTB and ANK1) will cover 94% (47 of 50 pa-
tients) of the diagnosis of HS. This could provide a
cheaper and more convenient method than current
strategies for diagnosis of HS. Regarding to the diag-
nostic guidelines suggested by international working
parties, we suggest that genetic test should be con-
ducted at least in patients without clues of laboratory
tests in spite of clinically suspected HS.
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Conclusions
This constitutes the first large-scaled genetic study of
Korean patients with HS. We detected 54 significant
HS-related mutations, including 46 novel mutations in
RBC membrane protein-encoding genes. We demon-
strated that multi-gene target sequencing is sensitive
and feasible that can be used as a powerful tool for diag-
nosing HS. Considering the discrepancies between clin-
ical and molecular diagnoses, use of molecular genetics
analysis provides an effective method for improving the
accuracy of HS diagnosis.
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